New York State Approves Columbia University’s 467-Gene Cancer Panel
NEW YORK, NY — (September 23, 2015) — The Laboratory of Personalized Genomic Medicine at Columbia University Medical Center (CUMC) has been granted full approval by the New York State Department of Health for the Columbia Combined Cancer Panel, (CCCP). This panel queries 467 cancer-related genes and was designed in collaboration with Columbia University Medical Center oncologists. The CCCP is one of the few approved clinical oncology panels of this type available in the New York area. This Columbia University laboratory provides services as part of ColumbiaDoctors, the faculty practice of CUMC.
A sequencing-only test, the CCCP uses the Illumina HiSeq2500 platform, and is conducted within Columbia University’s Personalized Genomic Medicine (PGM) CLIA-certified, CAP-accredited clinical genomics laboratory. Samples accepted for testing include paraffin-embedded tissue, fresh and frozen tissue--with or without microdissection to enrich for tumor--blood, and bone marrow.
The cancer panel joins the TruSeq Targeted Cancer Panel of New York State-approved oncology tests available within CUMC’s Laboratory of Personalized Genomic Medicine (PGM). PGM currently offers more than 14 clinical diagnostic tests in oncology, including a 46 gene targeted panel, targeted testing for KRAS, EGFR, BRAF, JAK2 V617F, clonality testing, BCR-ABL quantitative testing by RT-PCR, MGMT methylation analysis, and EGFRviii RNA expression. In addition, cancer whole exome and transcriptome sequencing is available by waivers on a case-by-case basis, while awaiting final state approval. A comprehensive array of fluorescent and chromogenic in-situ hybridization assays is also available through CUMC’s Division of Anatomic Pathology and the Cancer Cytogenetics Laboratory.
Laboratory of Personalized Genomic Medicine (PGM) - Columbia University Medical Center of the Department of Pathology and Cell Biology is a state-of-the-art diagnostic laboratory which performs cutting-edge tests in the areas of genetics, oncology, cytogenomics, and molecular microbiology, under the direction of Dr. Mahesh M. Mansukhani, MD. The Laboratory is accredited by CLIA, the College of American Pathologists (CAP) and the Clinical laboratory Evaluation Program (CLEP) of the New York State Department of Health. More information about PGM is available at www.pathology.columbia.edu/diagnostic/PGM.
ColumbiaDoctors, the faculty practice of Columbia University Medical Center, includes 1,500 physicians, surgeons, dentists, and advanced nurse practitioners, who offer more than 230 medical specialties and subspecialties. All ColumbiaDoctors are affiliated with NewYork-Presbyterian, the No. 1 hospital in New York. Offices are located throughout the Tri-State Area, including Midtown Manhattan, Washington Heights, the Hudson Valley, Rockland County, and Westchester. For more information, please visit www.columbiadoctors.org.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu.